Can entrectinib be purchased in domestic hospitals?

Entrectinib is a targeted therapy drug designed to treat certain types of cancer, primarily those carrying the NTRK gene fusion (fusion) or ROS1 gene rearrangement (rearrangement) tumors. It belongs to a class of drugs called tyrosine kinase inhibitors, which inhibit tumor growth and spread by targeting specific protein targets in cancer cells.

Entrectinib is now on the market in China and has been included in medical insurance. Patients can purchase it domestically. However, it is quite expensive, costing about 20,000 yuan. For specific price information and medical insurance reimbursement details, patients are advised to consult their local hospital pharmacy for accurate information. In comparison, the price of foreign generic drugs of entrectinib is relatively affordable, especially the generic drugs produced in Laos, which sell for only about one to two thousand yuan. It is worth mentioning that the ingredients of these generic drugs are basically the same as those of the original drugs.

Enrectinib is a multi-target inhibitor, its main effect is on NTRK protein and ROS1 protein. NTRKgene fusions and ROS1gene rearrangements are common genetic variations in some cancers, and they can promote the proliferation and growth of tumor cells. Entrectinib blocks the conduction of these abnormal signaling pathways by inhibiting the activity of these proteins, thereby inhibiting tumor growth.

The main clinical application of entrectinib is for tumors positive for NTRK gene fusion or ROS1 gene rearrangement. These tumors can include many types, such as lung cancer, breast cancer, colorectal cancer, etc. For those patients with these specific genetic variations, entrectinib offers a targeted treatment option.

Because NTRK gene fusions and ROS1 gene rearrangements can occur in multiple cancer types, entrectinib is considered a cross-tumor therapeutic agent. This means it doesn't just work on a specific type of tumor, but can show efficacy across multiple cancer types.